A new preoperative localization of pulmonary nodules guided by mixed reality: a pilot study of an animal model.
Mixed reality (MR)
localization
pilot study
pulmonary nodules
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
26
10
2022
accepted:
03
01
2023
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
11
2
2023
Statut:
ppublish
Résumé
With the popularity of high-resolution computed tomography (HRCT), more and more pulmonary nodules are being discovered. Video-assisted thoracoscopic surgery (VATS) has become the first choice for surgical treatment of pulmonary nodules. The use of accurate preoperative localization is crucial for successful resection in VATS. At present, there are many kinds of preoperative localization methods, but there are certain disadvantages. This study aimed to evaluate the feasibility and safety of mixed reality (MR)-guided pulmonary nodules localization, which is a new method that can benefit patients to a greater extent. By constructing an animal model of pulmonary nodules localization, 28 cases of pulmonary nodules were located by MR-guided localization. We recorded the localization accuracy, localization time, insertion attempts, and incidence of complications related to localization under MR-guidance. All 28 nodules were successfully located: the deviation of MR-guided localization was 5.71±2.59 mm, localization time was 8.07±1.44 min, and insertion attempts was 1. A pneumothorax and localizer dislodgement occurred in 1 case, respectively. Since preoperative localization is critical for VATS resection of pulmonary nodules, we investigated a new localization method. As indicated by our study, MR-guided localization of pulmonary nodules is feasible and safe, which is worthy of further research and promotion. We have also registered corresponding clinical trials to further investigate and help to improve our understanding of this technique.
Sections du résumé
Background
UNASSIGNED
With the popularity of high-resolution computed tomography (HRCT), more and more pulmonary nodules are being discovered. Video-assisted thoracoscopic surgery (VATS) has become the first choice for surgical treatment of pulmonary nodules. The use of accurate preoperative localization is crucial for successful resection in VATS. At present, there are many kinds of preoperative localization methods, but there are certain disadvantages. This study aimed to evaluate the feasibility and safety of mixed reality (MR)-guided pulmonary nodules localization, which is a new method that can benefit patients to a greater extent.
Methods
UNASSIGNED
By constructing an animal model of pulmonary nodules localization, 28 cases of pulmonary nodules were located by MR-guided localization. We recorded the localization accuracy, localization time, insertion attempts, and incidence of complications related to localization under MR-guidance.
Results
UNASSIGNED
All 28 nodules were successfully located: the deviation of MR-guided localization was 5.71±2.59 mm, localization time was 8.07±1.44 min, and insertion attempts was 1. A pneumothorax and localizer dislodgement occurred in 1 case, respectively.
Conclusions
UNASSIGNED
Since preoperative localization is critical for VATS resection of pulmonary nodules, we investigated a new localization method. As indicated by our study, MR-guided localization of pulmonary nodules is feasible and safe, which is worthy of further research and promotion. We have also registered corresponding clinical trials to further investigate and help to improve our understanding of this technique.
Identifiants
pubmed: 36762064
doi: 10.21037/tlcr-22-884
pii: tlcr-12-01-150
pmc: PMC9903086
doi:
Types de publication
Journal Article
Langues
eng
Pagination
150-157Informations de copyright
2023 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-884/coif). GD reports personal fees from ASTRA ZENECA, outside the submitted work. The other authors have no conflicts of interest to declare.
Références
AJR Am J Roentgenol. 1994 Aug;163(2):297-300
pubmed: 7518642
Ann Thorac Surg. 2020 May;109(5):1566-1573
pubmed: 32032573
Transl Lung Cancer Res. 2021 Nov;10(11):4152-4160
pubmed: 35004246
Plast Reconstr Surg. 2017 Nov;140(5):1066-1070
pubmed: 29068946
Cancer. 2000 Dec 1;89(11 Suppl):2474-82
pubmed: 11147630
J Med Internet Res. 2021 Aug 19;23(8):e24152
pubmed: 34420929
JAMA Netw Open. 2020 Sep 1;3(9):e2016271
pubmed: 32940677
J Thorac Dis. 2016 Oct;8(Suppl 9):S749-S755
pubmed: 28066679
Thorax. 2018 Aug;73(8):741-747
pubmed: 29661918
Interact Cardiovasc Thorac Surg. 2019 Sep 1;29(3):494
pubmed: 31106329
Ann Thorac Med. 2019 Jul-Sep;14(3):205-212
pubmed: 31333771
Front Oncol. 2021 Oct 27;11:707425
pubmed: 34778026
J Thorac Cardiovasc Surg. 2012 Apr;143(4):809-14
pubmed: 22104686
J Clin Med. 2022 Jan 17;11(2):
pubmed: 35054164
Chest. 1999 Feb;115(2):563-8
pubmed: 10027460
J Thorac Cardiovasc Surg. 2015 Jan;149(1):26-31
pubmed: 25293355
Transl Lung Cancer Res. 2021 Nov;10(11):4174-4184
pubmed: 35004248
J Thorac Dis. 2021 Dec;13(12):6994-7005
pubmed: 35070382
Chest. 1993 Sep;104(3):953-4
pubmed: 8365319
Eur J Cardiothorac Surg. 1998 Sep;14(3):265-70
pubmed: 9761435
J Thorac Cardiovasc Surg. 2018 Nov;156(5):1974-1983.e1
pubmed: 30119900
Thorac Cancer. 2018 Sep;9(9):1145-1150
pubmed: 30047619
Eur J Cardiothorac Surg. 2004 Mar;25(3):429-33
pubmed: 15019673
Surg Endosc. 2011 Jun;25(6):1723-9
pubmed: 21181200
J Thorac Cardiovasc Surg. 2016 Aug;152(2):535-544.e2
pubmed: 27189890
J Vasc Interv Radiol. 2019 Mar;30(3):453-459
pubmed: 30819493
Radiology. 2006 Feb;238(2):497-504
pubmed: 16436814
Front Med (Lausanne). 2021 Apr 14;8:661956
pubmed: 33937298